Cubist Asks High Court To Review Nixing Of Cubicin Patents
Law360, New York (May 16, 2016, 2:05 PM EDT) -- Lower courts erred by effectively creating new rules for evaluating a patent's obviousness when they examined and invalidated the asserted claims of four of the five patents covering the antibiotic Cubicin, Cubist Pharmaceuticals Inc. has told the U.S. Supreme Court.
The District of Delaware and the Federal Circuit erred by holding that secondary considerations — such as sales figures — must be comparable in scope with an invention's claimed features so that they may be given significant weight as part of a patent's obviousness analysis, and by determining that if any "long-felt needs" addressed by an invention are to be weighed,...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!